Biochemical Assessment of ACE Expression  and Progranulin, Sphingosine levels  in Overactive Thyroid with Malignant Nodule Patients

Saif. M. Hasan

Authors

Saif. M. Hasan Anesthesia Techniques Department, College of Health & Medical Technologies ,The University of Mashreq in Baghdad, Iraq

Keywords:

ACE Expression, Progranulin, Sphingosine

Abstract

Background: Thyroid nodules are a common finding in clinical settings, with their occurrence ranging approximately from 19% to 68% in the general population when assessed using ultrasonography. Thyroid-stimulating hormone (TSH) is a crucial regulator of thyroid growth and function, acting through TSH receptor activation. Elevated TSH levels have been linked to an increased risk of thyroid cancer, according to several studies. Materials and methods: A total of sixty blood samples were obtained from the laboratories of Kirkuk Hospital between (September 2024 and January 2025). The samples were subsequently categorized into two primary groups: a control group and a group comprising patients with malignant thyroid nodules and hyperthyroidism. Determination of TSH and anti-TPO by one-step sandwich enzyme immunoassay method. Determination of the concentrations of ACE , Progranulin, and Sphingosine by ELISA kit. Results; When comparing to the control group, the patient malignant nodule hyperthyroidism group's TSH and anti-TPO levels significantly increase (P˂0.01). The findings indicated that, in comparison to the control group, the group's ACE activity (IU/L) had significantly increased (P ˂0.01) and FC had significantly increased (P ˂0.05). When comparing to the control group, the levels of progranulin pg/ml in the malignant nodule hyperthyroidism group were significantly higher (P ˂0.001). Conclusion:- The study revealed a significant elevations in current study biomarkers among thyroid cancer patients compared to the control group, TSH and Anti-TPO levels were markedly increased suggesting underlying thyroid dysfunction and autoimmune involvement. ACE activity possibly linked to tumor-associated inflammation, fibrosis, or angiogenesis. Progranulin levels indicating its potential role as a biomarker for aggressive thyroid cancer.

References

S. D. Dadigamuwage, G. J. Kottegoda, D. E. Kannangara, et al., “Serum Thyroid-Stimulating Hormone (sTSH) Levels as a Predictor of Thyroid Malignancy: A Retrospective Analysis of 102 Patients,” Cureus, vol. 17, no. 4, p. e81599, Apr. 2025, doi: 10.7759/cureus.81599.

S. D. Dadigamuwage, G. J. Kottegoda, D. E. Kannangara, J. K. Bhagya, S. Suganthini, and S. A. Gunawardena, “Serum Thyroid-Stimulating Hormone (sTSH) Levels as a Predictor of Thyroid Malignancy: A Retrospective Analysis of 102 Patients,” Cureus, vol. 17, no. 4, p. e81599, 2025.

K. Gewert, G. Topi, T. Planck, and J. Calissendorff, “Thyroid peroxidase antibodies and their role in predicting outcomes in Graves’ disease treatment,” Front. Endocrinol., vol. 16, p. 1517283, 2025, doi: 10.3389/fendo.2025.1517283.

S. Kumar, F. Mohsin, K. Abhishek, and P. K. Jha, “Anti-TPO antibody, thyroglobulin antibody, and thyroid hormone levels in breast lump patients and their association with prognosis: A prospective study,” Int. J. Med. Public Health, vol. 15, no. 1, Jan.–Mar. 2025.

A. J. Turner and N. M. Hooper, “The angiotensin–converting enzyme gene family: Genomics and pharmacology,” Trends Pharmacol. Sci., vol. 23, no. 4, pp. 177–183, 2002.

V. Khurana and B. Goswami, “Angiotensin converting enzyme (ACE),” Clin. Chim. Acta, vol. 524, pp. 113–122, 2022.

A. Gulbins, G.-E. Görtz, E. Gulbins, and A. Eckstein, “Sphingolipids in thyroid eye disease,” Front. Endocrinol., vol. 14, p. 1170884, 2023.

K. A. Becker, R. Halmer, L. Davies, et al., “Blockade of experimental multiple sclerosis by inhibition of the acid sphingomyelinase/ceramide system,” Neurosignals, vol. 25, pp. 88–97, 2017, doi: 10.1159/000484621.

S. Walter, E. Gulbins, R. Halmer, et al., “Pharmacological inhibition of acid sphingomyelinase ameliorates experimental autoimmune encephalomyelitis,” Neurosignals, vol. 27, pp. 20–31, 2019, doi: 10.33594/000000183.

N. Beckmann, K. A. Becker, S. Walter, et al., “Regulation of arthritis severity by the acid sphingomyelinase,” Cell Physiol. Biochem., vol. 43, pp. 1460–1471, 2017, doi: 10.1159/000481968.

S. Schiffmann, N. Ferreiros, K. Birod, et al., “Ceramide synthase 6 plays a critical role in the development of experimental autoimmune encephalomyelitis,” J. Immunol., vol. 188, pp. 5723–5733, 2012, doi: 10.4049/jimmunol.1103109.

T. Zanocco Marani, A. Bateman, G. Romano, et al., “Biological activities and signaling pathways of the granulin/epithelin precursor,” Cancer Res., vol. 59, pp. 5331–5340, 1999.

T. Baba, H. B. Hoff III, H. Nemoto, et al., “Acrogranin… precursor of granulins and epithelins,” Mol. Reprod. Dev., vol. 34, pp. 233–243, 1993.

R. Tanimoto, K. G. Lu, S. Q. Xu, et al., “Mechanisms of progranulin action and regulation in genitourinary cancers,” Front. Endocrinol., vol. 7, p. 100, 2016.

A. Williams, E. C. Wang, L. Thurner, and C. J. Liu, “Novel insights into TNF receptor… progranulin pathways,” Arthritis Rheumatol., vol. 68, pp. 2845–2856, 2016.

R. Hrabal, Z. Chen, S. James, et al., “The hairpin stack fold… protein growth factors,” Nat. Struct. Biol., vol. 3, pp. 747–752, 1996.

D. Dembélé and P. Kastner, “Fold change rank ordering statistics…,” BMC Bioinformatics, vol. 15, p. 14, 2014, doi: 10.1186/1471-2105-15-14.

D. J. Stocker and H. B. Burch, “Thyroid cancer yield in patients with Graves’ disease,” Minerva Endocrinol., vol. 28, pp. 205–212, 2003.

Y. Shi, M. Zou, and N. R. Farid, “Expression of thyrotropin receptor gene…,” Clin. Endocrinol., vol. 39, pp. 269–274, 1993.

L. Golbert, et al., “Serum TSH levels as a predictor of malignancy in thyroid nodules,” PLoS One, vol. 12, no. 11, p. e0188123, 2017, doi: 10.1371/journal.pone.0188123.

Amudala, et al., “Utility of Serum TSH Levels as a Predictor of Malignancy…,” Int. J. Curr. Pharm. Rev. Res.

T. Awal, S. Nabila, M. S. Yesmin, et al., “Serum thyroid autoantibodies in malignant thyroid nodules,” Bangabandhu Sheikh Mujib Med. Univ. J., vol. 17, p. e74632, 2024.

C. de Micco, V. Savchenko, R. Giorgi, et al., “Utility of malignancy markers in FNAC…,” Br. J. Cancer, vol. 98, pp. 818–823, 2008.

J. Maruta, et al., “Value of thyroid specific peroxidase and Ki-67…,” Diagn. Cytopathol., vol. 43, pp. 202–209, 2015.

D. Okwan-Duodu, J. Landry, X. Z. Shen, and R. Diaz, “Angiotensin-converting enzyme and the tumor microenvironment…,” Am. J. Physiol., vol. 305, no. 3, pp. R205–R215, 2013.

E. D. L. Brown, B. Obeng-Gyasi, J. E. Hall, and S. Shekhar, “The thyroid hormone axis and female reproduction,” Int. J. Mol. Sci., vol. 24, p. 9815, 2023.

Y. Yamamoto, M. Takemura, G. Serrero, et al., “Increased serum GP88 concentrations…,” Inflammation, vol. 37, pp. 1806–1813, 2014.

M. Edelman, J. Feliciano, B. Yue, et al., “GP88 (progranulin)… lung carcinoma,” Hum. Pathol., vol. 45, pp. 1893–1899, 2014.

S. Bouchet, R. Tang, F. Fava, et al., “CNGRC-GG-D(KLAKLAK)2 peptide induces…,” Oncotarget, vol. 7, pp. 19445–19464, 2015.

M. O. Azazzi, et al., “Prognostic value of serum progranulin…,” Hematol. Transfus. Cell Ther., vol. 45, no. 1, pp. 25–31, 2023.

V. Abella, J. Pino, M. Scotece, et al., “Progranulin as a biomarker…,” Drug Discov. Today, vol. 22, pp. 1557–1564, 2017.

D. H. Koo, C. Y. Park, E. S. Lee, et al., “Progranulin as a prognostic biomarker…,” PLoS One, vol. 7, p. e39880, 2012.

F. Arechavaleta-Velasco, C. E. Perez-Juarez, G. L. Gerton, and L. Diaz-Cueto, “Progranulin and its biological effects in cancer,” Med. Oncol., vol. 34, p. 194, 2017.

A. M. Carlson, M. J. Maurer, K. M. Goergen, et al., “Utility of progranulin… ovarian cancer,” Cancer Epidemiol. Biomarkers Prev., vol. 22, pp. 1730–1735, 2013.

S. Demorrow, “Progranulin: a novel regulator…,” Transl. Gastrointest. Cancer, vol. 2, pp. 145–151, 2013.

K. R. Tkaczuk, B. Yue, M. Zhan, et al., “Increased circulating level of GP88…,” Breast Cancer (Auckl), vol. 5, pp. 155–162, 2011.

M. J. Edelman, J. Feliciano, B. Yue, et al., “GP88 (progranulin)…,” Hum. Pathol., vol. 45, pp. 1893–1899, 2014.

N. Pyne, F. Tonelli, K. G. Lim, et al., “Sphingosine 1-phosphate signalling in cancer,” Biochem. Soc. Trans., vol. 40, pp. 94–100, 2012.

P. Wang, Y. Yuan, W. Lin, et al., “Roles of sphingosine-1-phosphate signaling in cancer,” Cancer Cell Int., vol. 19, p. 295, 2019, doi: 10.1186/s12935-019-1014-8.